The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II). - 2024
The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II).
Acid alpha-glucosidase deficiency; Acid maltase deficiency; Glycogen storage disease (GSD) type II; Lysosomal storage disease; Pompe disease; Humans; Critical Pathways; Europe; Glycogen Storage Disease Type II/metabolism; Glycogen Storage Disease Type II/diagnosis; Glycogen Storage Disease Type II; Genetics (clinical); Pharmacology (medical)
Abstract :
[en] Clinical pathway recommendations (CPR) are based on existing guidelines and deliver a short overview on how to deal with a specific diagnosis, resulting therapy and follow-up. In this paper we propose a methodology for developing CPRs for Pompe disease, a metabolic myopathy caused by deficiency of lysosomal acid alpha-glucosidase. The CPR document was developed within the activities of the MetabERN, a non-profit European Reference Network for Metabolic Diseases established by the European Union. A working group was selected among members of the MetabERN lysosomal storage disease subnetwork, with specific expertise in the care of Pompe disease, and patient support group representatives. The working strategy was based on a systematic literature search to develop a database, followed by quality assessment of the studies selected from the literature, and by the development of the CPR document according to a matrix provided by MetabERN. Quality assessment of the literature and collection of citations was conducted according to the AGREE II criteria and Grading of Recommendations, Assessment, Development and Evaluation methodology. General aspects were addressed in the document, including pathophysiology, genetics, frequency, classification, manifestations and clinical approach, laboratory diagnosis and multidisciplinary evaluation, therapy and supportive measures, follow-up, monitoring, and pregnancy. The CPR document that was developed was intended to be a concise and easy-to-use tool for standardization of care for patients among the healthcare providers that are members of the network or are involved in the care for Pompe disease patients.
Disciplines :
Human health sciences: Multidisciplinary, general & others
Author, co-author :
Parenti, Giancarlo ; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands. parenti@unina.it ; Telethon Institute of Genetics and Medicine, Via Campi Flegrei 34, Pozzuoli, Naples, Italy. parenti@unina.it ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy. parenti@unina.it ; Azienda Ospedaliera Universitaria Federico II, Naples, Italy. parenti@unina.it
Fecarotta, Simona; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy ; Azienda Ospedaliera Universitaria Federico II, Naples, Italy
Alagia, Marianna; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy ; Azienda Ospedaliera Universitaria Federico II, Naples, Italy
Attaianese, Federica; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy
Verde, Alessandra; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy ; Azienda Ospedaliera Universitaria Federico II, Naples, Italy
Tarallo, Antonietta; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Telethon Institute of Genetics and Medicine, Via Campi Flegrei 34, Pozzuoli, Naples, Italy ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy
Gragnaniello, Vincenza; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, Naples, Italy
Ziagaki, Athanasia; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Endocrinology and Metabolism, Center of Excellence for Rare Metabolic Diseases in Adults, Charite-Universitätsmedizin Berlin, Berlin, Germany
Guimaraes, Maria Jose'; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Pneumology Department, Reference Center on Lysosomal Storage Disorders, Hospital Senhora da Oliveira, Guimarães, Portugal
Aguiar, Patricio; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Clinica Universitaria de Medicina I, Universidade de Lisboa, Lisbon, Portugal
Hahn, Andreas; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Child Neurology, Justus-Liebig University, Giessen, Germany
Azevedo, Olga; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Cardiology Department, Reference Center on Lysosomal Storage Disorders, Hospital Senhora da Oliveira, Guimarães, Portugal ; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal ; ICVS/3Bs PT Government Associate Laboratory, Braga/Guimarães, Portugal
Donati, Maria Alice; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Metabolic and Neuromuscular Unit, Meyer Children Hospital-University of Florence, Florence, Italy
Kiec-Wilk, Beata; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Unit of Rare Metabolic Diseases, Jagiellonian University Medical College, Kraków, Poland ; The John Paul II Specjalist Hospital in Kraków, Kraków, Poland
Scarpa, Maurizio; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Centro Coordinamento Regionale Malattie Rare, Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy
van der Beek, Nadine A M E; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Center for Lysosomal and Metabolic Diseases, Erasmus MC, Erasmus University Medical Center, Rotterdam, Netherlands
Del Toro Riera, Mireja; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Metabolic Unit, Department of Pediatric Neurology, Hospital Universitario Vall d'Hebron Barcelona, Barcelona, Spain
Germain, Dominique P; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Division of Medical Genetics, University of Versailles, Montigny, France
Huidekoper, Hidde; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands
van den Hout, Johanna M P; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands ; Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands
van der Ploeg, Ans T; MetabERN Subnetwork for Lysosomal Disorders, Rotterdam, The Netherlands. a.vanderploeg@erasmusmc.nl ; Center for Lysosomal and Metabolic Diseases, Erasmus MC, Erasmus University Medical Center, Rotterdam, Netherlands. a.vanderploeg@erasmusmc.nl
and the MetabERN Subnetwork for Lysosomal Disorders
Debray, François-Guillaume ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Maladies métaboliques d'origine génétique
The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II).
We gratefully acknowledge members of MetabERN Subnetwork for Lysosomal Disorders who reviewed the manuscript. MetabERN Subnetwork for Lysosomal Disorders: Ivo Baric1, Spyros Batzios2, Nadia Belmatoug3, Andrea Bordugo4, Annet M. Bosch5, Anais Brassier6, Alberto Burlina7, David Cassiman8, Brigitte Chabrol9, Efstathia Chronopoulou10, Maria Luz Couce-Pico11, Niklas Darin12, Anibh M. Das13, Francois G. Debray14, Patrick Deegan15, Luisa M. de Abreu Freire Diogo Matos16, Javier De Las Heras Montero17, Maja Di Rocco18, Dries Dobbelaere19, Francois Eyskens20, Ana Ferreira21, Ana M. Gaspar22, Serena Gasperini23, Antonio Gonz\u00E1lez-Meneses L\u00F3pez24, Salvatore Grosso25, Nathalie Guffon-Fouilhoux26, Julia Hennermann27, Tarekegn G. Hiwot28, Simon Jones29, Sandra Kingma20, Veroniki Komninaka30, Elena Mart\u00EDn-Hern\u00E1ndez31, Esmeralda Martins32, Diana Miclea33, Gy\u00F6rgy Pfliegler34, Esmeralda Rodrigues35, Dariusz Rokicki36, Dominique Roland37, Frank Rutsch38, Alessandro Salviati39, Ivailo Tournev40, Kurt Ullrich41, Peter M. van Hasselt42, Suresh Vijay43, Natalie Weinhold44, Peter Witters45, Jiri Zeman46. 1University Hospital Center Zagreb, Croatia; 2Great Ormond Street Hospital NHS Foundaton Trust, London, United Kingdom; 3H\u00F4pital Beaujon de Paris, France; 4Azienda Ospedaliera Universitaria Integrata di Verona, Italy; 5Academic Medical Center of Amsterdam, Netherlands; 6 Hospital Necker des Enfants Malades, APHP, University Paris Descartes, Paris, France.; 7 University Hospital of Padova, Italy; 8 University of KU Leuven, Belgium; 9University hospital of Marseille, France; 10Department of Inherited Metabolic Disease, Division of Women's and Children's Services, University Hospitals Bristol NHS Foundation Trust, Bristol, UK; 11University Clinical Hospital of Santiago de Compostela, Spain; 12Sahlgrenska Hospital, Gothenburg, Sweden; 13Hannover Medical School, Germany; 14Centre Hospitalier Universitaire de Li\u00E8ge, Belgium; 15Cambridge University Hospitals NHS Foundation Trust (CUH), United Kingdom; 16Centro Hospitalar e Universit\u00E1rio de Coimbra, EPE, Portugal; 17Hospital Universitario Cruces, Spain; 18G. Gaslini Institute (IRCCS), Genova, Italy; 19University Hospital of Lille, France; 20University Hospital of Antwerp, Center of Inherited Metabolic Diseases, Belgium; 21Centro Hospitalar Lisboa Central, Portugal; 22Centro Hospitalar Lisboa Norte, EPE, Portugal; 23San Gerardo Hospital, Monza, Italy; 24Hospital Virgen del Rocio, Sevilla, Spain; 25Azienda Ospedaliera Universitaria Senese, Italy; 26University Hospital of Lyon, France; 27University Medical Center Mainz, Germany; 28University Hospital of Birmingham NHS Foundation Trust, United Kingdom; 29Central Manchester University Hospitals NHS Trust, United Kingdom; 30Laiko General Hospital of Athene, Greece; 31Hospital Universitario 12 de Octubre, Madrid, Spain; 32Centro Hospitalar do Porto, EPE (CHP), Portugal; 33Clinical Emergency Hospital for children, Cluj-Napoca, Romania; 34University of Debrecen, Hungary; 35Centro Hospitalar do Sao Joao, EPE, Portugal; 36The Children\u2019s Memorial Health Institute of Warsaw, Poland; 37Belgium Center Inter Institutional for Metabolic Diseases (CIMM); 38University Hospital of Muenster, Germany; 39Department of Biotechnology, University of Verona, Italy; 40University hospital \"Alexandrovska\", Sofia, Bulgaria; 41University Medical Center Hamburg-Eppendorf, Germany; 42University Medical Center Utrecht (UMCU), Netherlands; 43Birmingham Children\u2019s Hospital NHS Foundation Trust, United Kingdom; 44Charit\u00E9-Universit\u00E4tsmedizin, Berlin, Germany; 45Universitair Ziekenhuis of Leuven, Belgium; 46General University Hospital in Prague, Czech Republic.GP has received funding for research and clinical trials and advisory fees from Sanofi-Genzyme, Amicus Therapeutics, Orchard, Synageva/Alexion, BioMarin, Denali, Takeda. SF has received honoraria, consulting fees, speaker fees and travel reimbursement. From Sanofi, Amicus, Alexion, Chiesi. MJG has received educational and research grants from Sanofi Genzyme. PRTA received grant/research support from Takeda, and speaker/travel. honoraria from Takeda, Sanofi-Genzyme, BioMarin, Ultragenyx, Alexion, Amicus Therapeutics, and Chiesi.. OA has received educational/research grants from Shire Human Genetic Therapies/Takeda and travel/accommodation support for conferences from Shire Human Genetic. Therapies/Takeda, Amicus and Sanofi Genzyme. MAD received travel grants for scientific meetings and honoraria for speaking. engagements from Shire International, Sanofi Genzyme and BioMarin. MS has received honoraria, research and travel grants from Alexion, BioMarin. Pharmaceutical Inc., Chiesi, Sanofi Genzyme, Shire, Ultragenix and Sangamo. NAMEvdeB has received consulting fees and travel reimbursement from Sanofi andAmicus Therapeutics and received funding for research, clinical trials, and advisory fees from Sanofi. MDTR has received consulting fees and speaker honoraria, travel expenses, and congress fees from Biomarin, Sanofi Genzyme, Takeda,and has participated in trials sponsored by Orphazyme, Takeda, Vtesse-Sucampo Mallinckrodt). DPG has received consulting honoraria from Chiesi, Idorsia Pharmaceuticals, Sanofi and Takeda, and speaker honoraria and travel support from Sanofi and Takeda. HH reports advisory board fees, speaker fee, and a clinical trial agreement from BioMarin. JMPvdH received funding for research, clinical trials, and advisory fees from Sanofi-Genzyme, Amicus Therapeutics, BioMarin, Sarepta, Denali, Takeda and Chiesi. ATvdP has received grant for clinical trials conduction from Amicus Therapeutics andSanofi-Genzyme. MA, FA, AV, AT, VG, AZ, AH, BKW have no conflicts of interest to declare.
L. Shea N. Raben Autophagy in skeletal muscle: implications for Pompe disease Int J Clin Pharmacol Ther 2009 47 Suppl 1 42 47
R. Myerowitz R. Puertollano N. Raben Impaired autophagy: the collateral damage of lysosomal storage disorders EBioMedicine 2021 63 103166 1:CAS:528:DC%2BB3MXotlOls7k%3D 33341443
J.A. Lim L. Li O. Kakhlon R. Myerowitz N. Raben Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease Autophagy 2015 11 2 385 402 1:CAS:528:DC%2BC2MXhvVWqt7%2FK 25758767 4502791
A. Tarallo C. Damiano S. Strollo N. Minopoli A. Indrieri E. Polishchuk et al. Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease EMBO Mol Med 2021 13 11 e14434 1:CAS:528:DC%2BB3MXitFKksb7O 10.15252/emmm.202114434 34606154 8573602
A.T. van der Ploeg P. Laforet C. Hollak R. Lachmann Pompe disease Inherited metabolic disease in adults: a clinical guide 2016 Oxford University Press 353 358
F. Martiniuk M. Bodkin S. Tzall R. Hirschhorn Isolation and partial characterization of the structural gene for human acid alpha glucosidase DNA Cell Biol 1991 10 4 283 292 1:CAS:528:DyaK3MXlt1yrtr8%3D 1674202
A.T. van der Ploeg A.J. Reuser Pompe's disease Lancet 2008 372 9646 1342 1353 18929906
D.O.S. de Faria S.L.M. In't Groen M. Hoogeveen-Westerveld M.Y. Nino A.T. van der Ploeg A.J. Bergsma et al. Update of the Pompe variant database for the prediction of clinical phenotypes: novel disease-associated variants, common sequence variants, and results from newborn screening Hum Mutat 2021 42 2 119 134 33560568
A.J. Bergsma J.J. van den Dorpel H.J. van den Hout N.A. van der Beek B. Schoser et al. A genetic modifier of symptom onset in Pompe disease EBioMedicine 2019 43 553 561 30922962 6562017
O. Musumeci A. Thieme K.G. Claeys S. Wenninger R.A. Kley M. Kuhn et al. Homozygosity for the common GAA gene splice site mutation c.-32–13T>G in Pompe disease is associated with the classical adult phenotypical spectrum Neuromuscul Disord 2015 25 9 719 724 26231297
M.M. Hermans D. van Leenen M.A. Kroos C.E. Beesley A.T. Van Der Ploeg H. Sakuraba et al. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II Hum Mutat 2004 23 1 47 56 1:CAS:528:DC%2BD2cXptlOjug%3D%3D 14695532
A.J.J. Reuser A.T. van der Ploeg Y.H. Chien J. Llerena Jr M.A. Abbott P.R. Clemens et al. On behalf of the Pompe registry sites. GAA variants and phenotypes among 1079 patients with Pompe disease: data from the Pompe registry Hum Mutat 2019 40 11 2146 2164 31342611 6852536
M.Y. Niño M. Wijgerde D.O.S. de Faria M. Hoogeveen-Westerveld A.J. Bergsma M. Broeders et al. Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience Eur J Hum Genet 2021 29 3 434 446 33162552
C.M. van Gelder M. Hoogeveen-Westerveld M.A. Kroos I. Plug A.T. van der Ploeg A.J. Reuser Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease J Inherit Metab Dis 2015 38 2 305 314 24715333
S.G. Banugaria S.N. Prater T.T. Patel S.M. Dearmey C. Milleson K.B. Sheets et al. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT PLoS ONE 2013 8 6 e67052 1:CAS:528:DC%2BC3sXhtV2qurfL 10.1371/journal.pone.0067052 23825616 3692419
C. Semplicini P. Letard M. De Antonio N. Taouagh B. Perniconi F. Bouhour French Pompe Study Group et al. Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study J Inherit Metab Dis 2018 41 6 937 946 1:CAS:528:DC%2BC1cXhs1Snu7zM 30155607
C.R. Scott S. Elliott N. Buroker L.I. Thomas J. Keutzer M. Glass et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry J Pediatr 2013 163 2 498 503 1:CAS:528:DC%2BC3sXjsFynsb0%3D 23465405 3725184
O.A. Bodamer C.R. Scott R. Giugliani Pompe Disease Newborn Screening Working Group. Newborn screening for Pompe disease Pediatrics 2017 140 Suppl 1 4 13
Y.H. Chien W.L. Hwu N.C. Lee Newborn screening: Taiwanese experience Ann Transl Med 2019 7 13 281 1:CAS:528:DC%2BB3cXhvF2is78%3D 31392193 6642927
V. Gragnaniello P.W.W.M. Pijnappel A.P. Burlina S.L.M. In’t-Groen D. Gueraldi C. Cazzorla et al. Newborn screening for Pompe disease in Italy: long-term results and future challenges Mol Genet Metab Rep 2022 33 100929 1:CAS:528:DC%2BB38XislejtbzJ 36310651 9597184
T.P. Mechtler S. Stary T.F. Metz V.R. De Jesús S. Greber-Platzer A. Pollak et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria Lancet 2012 379 9813 335 341 22133539
N. Elenga A. Verloes Y. Mrsic C. Basurko R. Schaub E. Cuadro-Alvarez et al. Incidence of infantile Pompe disease in the Maroon population of French Guiana BMJ Paediatr Open 2018 2 1 e000182 10.1136/bmjpo-2017-000182 29637184 5842995
M.L. Hagemans L.P. Winkel W.C. Hop A.J. Reuser P.A. Van Doorn A.T. Van der Ploeg Disease severity in children and adults with Pompe disease related to age and disease duration Neurology 2005 64 12 2139 2141 1:STN:280:DC%2BD2MzjsFSmtw%3D%3D 15985590
M.A. Kroos R.J. Pomponio M.L. Hagemans J.L. Keulemans M. Phipps M. DeRiso et al. Broad spectrum of Pompe disease in patients with the same c.-32–13T->G haplotype Neurology 2007 68 2 110 115 1:STN:280:DC%2BD2s%2FhsFSiug%3D%3D 17210890
N. Preisler Z. Lukacs L. Vinge K.L. Madsen E. Husu R.S. Hansen et al. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies Mol Genet Metab 2013 110 3 287 289 1:CAS:528:DC%2BC3sXhsVSktL3I 24011652
T. Sawada J. Kido K. Nakamura Newborn screening for Pompe disease Int J Neonatal Screen 2020 6 2 31 33073027 7423004
L.D. Smith M.N. Bainbridge R.B. Parad A. Bhattacharjee Second tier molecular genetic testing in newborn screening for pompe disease: landscape and challenges Int J Neonatal Screen 2020 6 2 32 32352041 7189780
C.G. van El T. Rigter A.J. Reuser A.T. van der Ploeg S.S. Weinreich M.C. Cornel Newborn screening for pompe disease? A qualitative study exploring professional views BMC Pediatr 2014 14 203 25124044 4139142
S.S. Weinreich T. Rigter C.G. van El W.J. Dondorp P.J. Kostense A.T. van der Ploeg et al. Public support for neonatal screening for Pompe disease, a broad-phenotype condition Orphanet J Rare Dis 2012 7 15 22413814 3351372
S. Singh J. Ojodu A.R. Kemper W.K.K. Lam S.D. Grosse Implementation of newborn screening for conditions in the United States first recommended during 2010–2018 Int J Neonatal Screen 2023 9 2 20 37092514 10123615
M.H. Gelb F. Turecek C.R. Scott N.A. Chamoles Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders J Inherit Metab Dis 2006 29 2–3 397 404 1:CAS:528:DC%2BD28XlsV2ltbc%3D 16763908 2488386
P. Labrousse Y.H. Chien R.J. Pomponio J. Keutzer N.C. Lee V.R. Akmaev et al. Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program Mol Genet Metab 2010 99 4 379 383 1:CAS:528:DC%2BC3cXjt1elsLc%3D 20080426
M. Kroos M. Hoogeveen-Westerveld A. van der Ploeg A.J. Reuser The genotype-phenotype correlation in Pompe disease Am J Med Genet C Semin Med Genet 2012 160C 1 59 68 22253258
A.T. van der Ploeg M.E. Kruijshaar A. Toscano P. Laforêt C. Angelini R.H. Lachmann European Pompe Consortium et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience Eur J Neurol 2017 24 6 768 10.1111/ene.13285 28477382
Pompe Disease Diagnostic Working Group B. Winchester D. Bali O.A. Bodamer C. Caillaud E. Christensen et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting Mol Genet Metab 2008 93 3 275 281
M. Savarese A. Torella O. Musumeci C. Angelini G. Astrea L. Bello et al. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease Neuromuscul Disord 2018 28 7 586 591 29880332
S.L.M. In’t Groen D.O.S. de Faria A. Iuliano J.M.P. van den Hout H. Douben T. Dijkhuizen et al. Novel GAA variants and mosaicism in Pompe disease identified by extended analyses of patients with an incomplete DNA diagnosis Mol Ther Methods Clin Dev 2020 17 337 348 32071926
A. Pascarella C. Terracciano O. Farina L. Lombardi T. Esposito F. Napolitano et al. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy J Cell Physiol 2018 233 8 5829 5837 1:CAS:528:DC%2BC1cXjtFarurs%3D 29215735
A. Hahn J.B. Hennermann M. Huemer C. Kampmann T. Marquardt E. Mengel et al. Diagnosis and care of infants and children with Pompe disease Klin Padiatr 2020 10.1055/a-1110-7335 32069498
J.T. Saville M. Fuller Experience with the urinary tetrasaccharide metabolite for Pompe disease in the diagnostic laboratory Metabolites 2021 11 7 446 1:CAS:528:DC%2BB3MXitlejtrvL 34357340 8305466
A. Tarallo A. Carissimo F. Gatto E. Nusco A. Toscano O. Musumeci et al. microRNAs as biomarkers in Pompe disease Genet Med 2019 21 3 591 600 1:CAS:528:DC%2BC1cXhtlWnt73F 29997386
A. Carrasco-Rozas E. Fernández-Simón M.C. Lleixà I. Belmonte I. Pedrosa-Hernandez E. Montiel-Morillo et al. Identification of serum microRNAs as potential biomarkers in Pompe disease Ann Clin Transl Neurol 2019 6 7 1214 1224 1:CAS:528:DC%2BC1MXhsVertr%2FM 31353854 6649638
M.J. Mackenbach E.A.J. Willemse J.J.A. van den Dorpel N.A.M.E. van der Beek J. Díaz-Manera D. Rizopoulos et al. Neurofilament light and its association with CNS involvement in patients with classic infantile Pompe disease Neurology 2023 101 6 e594 e601 1:CAS:528:DC%2BB3sXhvVaisrnL 10.1212/WNL.0000000000207482 37336766 10424841
Y.K. Hsu Y.H. Chien S. Shinn-Forng Peng W.L. Hwu W.T. Lee N.C. Lee et al. Evaluating brain white matter hyperintensity, IQ scores, and plasma neurofilament light chain concentration in early-treated patients with infantile-onset Pompe disease Genet Med 2023 25 1 27 36 1:CAS:528:DC%2BB3sXkt1agtA%3D%3D 36399131
L. Harlaar P. Ciet G. van Tulder E. Brusse R.G.M. Timmermans W.G.M. Janssen et al. Diaphragmatic dysfunction in neuromuscular disease, an MRI study Neuromuscul Disord 2022 32 1 15 24 34973872
L. Harlaar P. Ciet A.T. van der Ploeg E. Brusse N.A.M.E. van der Beek P.A. Wielopolski et al. Imaging of respiratory muscles in neuromuscular disease: a review Neuromuscul Disord 2018 28 3 246 256 1:STN:280:DC%2BC1MvntFaltQ%3D%3D 29398294
B.J. Ebbink E. Poelman F.K. Aarsen I. Plug L. Régal C. Muentjes et al. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain Dev Med Child Neurol 2018 60 6 579 586 29573408
B. Labella S. Cotti Piccinelli B. Risi F. Caria S. Damioli E. Bertella et al. A comprehensive update on late-onset Pompe disease Biomolecules 2023 13 9 1279 1:CAS:528:DC%2BB3sXitVGgtL3P 37759679 10526932
J.M. Van den Hout J.H. Kamphoven L.P. Winkel W.F. Arts J.B. De Klerk M.C. Loonen et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk Pediatrics 2004 113 5 e448 e457 10.1542/peds.113.5.e448 15121988
A.T. van der Ploeg P.R. Clemens D. Corzo D.M. Escolar J. Florence G.J. Groeneveld et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease N Engl J Med 2010 362 15 1396 1406 20393176
E. Kuperus M.E. Kruijshaar S.C.A. Wens J.M. de Vries M.M. Favejee J.C. van der Meijden et al. Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study Neurology 2017 89 23 2365 2373 1:CAS:528:DC%2BC2sXhvFWmsrrF 29117951
K. Gutschmidt O. Musumeci J. Díaz-Manera Y.H. Chien K.C. Knop S. Wenninger et al. STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa J Neurol 2021 268 7 2482 2492 1:CAS:528:DC%2BB3MXms1Gls7k%3D 33543425 7862044
I.A.M. Ditters H.H. Huidekoper M.E. Kruijshaar D. Rizopoulos A. Hahn T.E. Mongini European Pompe Consortium Project Group on Classic Infantile Pompe Disease et al. European Pompe Consortium project group on classic infantile Pompe disease. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium Lancet Child Adolesc Health 2022 6 1 28 37 1:CAS:528:DC%2BB38XntVChsrk%3D 34822769
S. Dalmia R. Sharma U. Ramaswami D. Hughes N. Jahnke D. Cole et al. Enzyme replacement therapy for late-onset Pompe disease Cochrane Database Syst Rev 2023 12 12 CD012993 10.1002/14651858.CD012993.pub2 38084761
J. Diaz-Manera P.S. Kishnani H. Kushlaf S. Ladha T. Mozaffar V. Straub COMET Investigator Group et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial Lancet Neurol 2021 20 12 1012 1026 1:CAS:528:DC%2BB38XntVCjs7w%3D 34800399
B. Schoser M. Roberts B.J. Byrne S. Sitaraman H. Jiang P. Laforêt PROPEL Study Group et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial Lancet Neurol 2021 20 12 1027 1037 1:CAS:528:DC%2BB38XntVCjs70%3D 34800400
E. Poelman J.J.A. van den Dorpel M. Hoogeveen-Westerveld J.M.P. van den Hout L.J. van der Giessen N.A.M.E. van der Beek et al. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients J Inherit Metab Dis 2020 43 6 1243 1253 1:CAS:528:DC%2BB3cXisFSmtbjJ 32506446 7689828
A.A. Khan L.E. Case M. Herbert S. DeArmey H. Jones K. Crisp et al. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature Genet Med 2020 22 5 898 907 1:CAS:528:DC%2BB3cXmtV2iug%3D%3D 31904026 7469631
Y.H. Chien W.H. Tsai C.L. Chang P.C. Chiu Y.Y. Chou F.J. Tsai et al. Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: evidence from real-world experiences Mol Genet Metab Rep 2020 23 100591 1:CAS:528:DC%2BB3cXotlaqs70%3D 32373469 7193123
S. Dhillon Avalglucosidase alfa: first approval Drugs 2021 81 15 1803 1809 1:CAS:528:DC%2BB3MXitlWgtLfM 34591286
P.S. Kishnani J. Diaz-Manera A. Toscano P.R. Clemens S. Ladha K.I. Berger COMET Investigator Group et al. Efficacy and safety of avalglucosidase alfa in patients with late-onset pompe disease after 97 weeks: a phase 3 randomized clinical trial JAMA Neurol 2023 80 6 558 567 37036722 10087094
P.S. Kishnani D. Kronn A. Brassier A. Broomfield J. Davison S.H. Hahn Mini-COMET Investigators et al. Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report Genet Med 2023 25 2 100328 1:CAS:528:DC%2BB38XjtFCkt7%2FP 36542086
B. Schoser A. Stewart S. Kanters A. Hamed J. Jansen K. Chan et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis J Neurol 2017 264 4 621 630 1:CAS:528:DC%2BC28XhtFGrt7fP 27372449
C.F. Yang C.C. Yang H.C. Liao L.Y. Huang C.C. Chiang H.C. Ho et al. Very early treatment for infantile-onset pompe disease contributes to better outcomes J Pediatr 2016 169 174 80.e1 10.1016/j.jpeds.2015.10.078 26685070
Schoser B, van der Beek NAME, Broomfield A, Brusse E, Diaz-Manera J, Hahn A, Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024. Eur J Neurol. 2024:e16383.
I.A.M. Ditters N.A.M.E. van der Beek E. Brusse A.T. van der Ploeg J.M.P. van den Hout H.H. Huidekoper Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study Orphanet J Rare Dis 2023 18 1 108 37158969 10169363
I.A.M. Ditters H.A. van Kooten N.A.M.E. van der Beek J.F. Hardon G. Ismailova E. Brusse et al. Home-based infusion of alglucosidase alfa can safely be implemented in adults with late-onset Pompe disease: lessons learned from 18,380 infusions BioDrugs 2023 37 5 685 698 1:CAS:528:DC%2BB3sXht1GjtLfE 37326923 10432339
P.S. Kishnani P.I. Dickson L. Muldowney J.J. Lee A. Rosenberg R. Abichandani et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction Mol Genet Metab 2016 117 2 66 83 1:CAS:528:DC%2BC2MXhvVCht7vJ 26597321
E. Poelman M. Hoogeveen-Westerveld J.M.P. van den Hout J.M.P. van den Hout R.G.M. Bredius A.C. Lankester et al. Effects of immunomodulation in classic infantile Pompe patients with high antibody titers Orphanet J Rare Dis 2019 14 1 71 1:STN:280:DC%2BB3cbntF2htw%3D%3D 30902109 6431009
C. Li A.K. Desai P. Gupta K. Dempsey V. Bhambhani R.J. Hopkin et al. Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction Genet Med 2021 23 5 845 855 1:CAS:528:DC%2BB3MXitFajtbw%3D 33495531 8107133
F. Deodato V.M. Ginocchio A. Onofri G. Grutter A. Germani C. Dionisi-Vici Immune tolerance induced using plasma exchange and rituximab in an infantile Pompe disease patient J Child Neurol 2014 29 6 850 854 23620524
A.K. Desai A.S. Rosenberg P.S. Kishnani The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease Clin Immunol 2020 219 108541 1:CAS:528:DC%2BB3cXhsV2lsrjP 32681978
A.K. Desai G. Shrivastava C.L. Grant R.Y. Wang T.D. Burt P.S. Kishnani An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation Front Immunol 2024 15 1360369 1:CAS:528:DC%2BB2cXhtV2isr3K 38524130 10959098
A.H. El-Gharbawy J. Mackey S. DeArmey G. Westby S.G. Grinnell P. Malovrh et al. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions Mol Genet Metab 2011 104 1–2 118 122 1:CAS:528:DC%2BC3MXhtFGlsLjF 21802969 3711228
V. Gragnaniello S. Fecarotta A. Pecoraro A. Tarallo A. Catzola G. Spadaro et al. Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa Neurol Sci 2019 40 7 1453 1455 1:STN:280:DC%2BB3cfkvFerug%3D%3D 30778879
D.D. Koeberl L.E. Case A. Desai E.C. Smith C. Walters S.O. Han et al. Improved muscle function in a phase I/II clinical trial of albuterol in Pompe disease Mol Genet Metab 2020 129 2 67 72 1:CAS:528:DC%2BC1MXitlynu7%2FJ 31839530
P. Colella F. Mingozzi Gene therapy for pompe disease: the time is now Hum Gene Ther 2019 30 10 1245 1262 1:CAS:528:DC%2BC1MXhvVOqs73E 31298581
J.C. Ullman K.T. Mellem Y. Xi V. Ramanan H. Merritt R. Choy et al. Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders Sci Transl Med 2024 16 730 eadf1691 1:CAS:528:DC%2BB2cXitVWmsL8%3D 10.1126/scitranslmed.adf1691 38232139
F. Carubbi A. Barbato A.B. Burlina F. Francini R. Mignani E. Pegoraro Italian Society of Human Nutrition Working Group on Nutrition in Lysosomal Storage Diseases et al. Nutrition in adult patients with selected lysosomal storage diseases Nutr Metab Cardiovasc Dis 2021 31 3 733 744 1:CAS:528:DC%2BB3MXht1altLk%3D 33589321
Morales JA, Anilkumar AC. Glycogen Storage Disease Type II. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. https://www.statpearls.com/point-of-care/22333. Accessed 16 Jul 2024
M.M. Favejee B.M. Huisstede J.B. Bussmann M.E. Kruijshaar A.T. van der Ploeg Physiotherapy management in late-onset Pompe disease: clinical practice in 88 patients Mol Genet Metab 2012 107 1–2 111 115 1:CAS:528:DC%2BC38Xht1Sku73L 22901700
M.M. Favejee L.E. van den Berg M.E. Kruijshaar S.C. Wens S.F. Praet W.W. Pim Pijnappel et al. Exercise training in adults with Pompe disease: the effects on pain, fatigue, and functioning Arch Phys Med Rehabil 2015 96 5 817 822 25499687
U. Mellies F. Stehling C. Dohna-Schwake R. Ragette H. Teschler T. Voit Respiratory failure in Pompe disease: treatment with noninvasive ventilation Neurology 2005 64 8 1465 1467 1:STN:280:DC%2BD2M3hslCjsQ%3D%3D 15851748
M. Boentert H. Prigent K. Várdi H.N. Jones U. Mellies A.K. Simonds et al. Practical recommendations for diagnosis and management of respiratory muscle weakness in late-onset Pompe disease Int J Mol Sci 2016 17 10 1735 27763517 5085764
B. Bembi E. Cerini C. Danesino M.A. Donati S. Gasperini L. Morandi et al. Management and treatment of glycogenosis type II Neurology 2008 71 23_Suppl 2 12 36
P.S. Kishnani R.D. Steiner D. Bali K. Berger B.J. Byrne L.E. Case et al. Pompe disease diagnosis and management guideline Genet Med 2006 8 5 267 288 16702877 3110959 Erratum in: Genet Med. 2006;8(6):382. ACMG Work Group on Management of Pompe Disease
Leslie N, Bailey L. Pompe Disease. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2007 Aug 31 [updated 2023 Nov 2].https://www.ncbi.nlm.nih.gov/books/NBK1261/
D. PGüngör M.E. Kruijshaar I. Plug D. Rizopoulos T.A. Kanters S.C. Wens et al. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up J Inherit Metab Dis 2016 39 2 253 260
A. Korlimarla G.A. Spiridigliozzi M. Stefanescu S.L. Austin P.S. Kishnani Behavioral, social and school functioning in children with Pompe disease Mol Genet Metab Rep 2020 25 100635 32793419 7414001
C. Angelini G. Siciliano Neuromuscular diseases and Covid-19: advices from scientific societies and early observations in Italy Eur J Transl Myol 2020 30 2 9032 32782765 7385692
U. Plöckinger N. Tiling L. Bosanska B. Temmesfeld-Wollbrueck K. Irlbacher V. Mezger et al. Multiple, successful pregnancies in Pompe disease JIMD Rep 2016 28 111 118 26572913
P.J. Rohman E. Scott L. Richfield U. Ramaswami D.A. Hughes Pregnancy and associated events in women receiving enzyme replacement therapy for late-onset glycogen storage disease type II (Pompe disease) J Obstet Gynaecol Res 2016 42 10 1263 1271 1:CAS:528:DC%2BC28Xhs1SktLnK 27384519
O. Goker-Alpan V.G. Kasturi M.K. Sohi R.P. Limgala S.L. Austin T. Jennelle et al. Pregnancy outcomes in late onset pompe disease Life 2020 10 9 194 32932790 7556025
J.M. de Vries J.D. Brugma L. Ozkan E.A. Steegers A.J. Reuser P.A. van Doorn et al. First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease Mol Genet Metab 2011 104 4 552 555 21967859